@article{TGH3693,
author = {Caterina Vivaldi and Alfredo Falcone and Lorenzo Fornaro},
title = {Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer},
journal = {Translational Gastroenterology and Hepatology},
volume = {2},
number = {2},
year = {2017},
keywords = {},
abstract = {Gastric cancer stands among the most common causes of cancer death worldwide (1). Median overall survival (OS) for patients with advanced disease is approximately 1 year and chemotherapy still represents the milestone of treatment in most patients (2). While first-line chemotherapy has a well-established role in gastric cancer management, during the past few years several trials clearly demonstrated a significant OS benefit for second-line therapy compared with best supportive care (BSC) alone (3); however, as the gain in survival is at best modest in absolute terms, a careful clinical selection is needed to identify patients who could benefit from salvage therapies (4). Moreover, no standard treatment exists after second-line failure. Thus, searching for new therapeutic opportunities in pretreated advanced gastric cancer patients is imperative for researchers and clinicians.},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/3693}
}